Synapse

← Cancer Treatment and Research Communications

Papers in Cancer Treatment and Research Communications

Page 6 · newest first

  1. Distinct molecular features of ovarian adult granulosa cell tumors and co-occurring primary malignancies–an exploratory case seriesCancer Treatment and Research Communications · 2026
  2. Early wound complications after soft tissue sarcoma surgery; Association with local recurrence and deathCancer Treatment and Research Communications · 2026
  3. BRAF V600E Co-mutations predict aggressive clinicopathological features in Chinese patients with differentiated thyroid cancer: A multicenter cohort studyCancer Treatment and Research Communications · 2026
  4. MIF −173 G>C polymorphism as a context-dependent modifier of solid cancer risk: A meta-analysisCancer Treatment and Research Communications · 2026
  5. Development and validation of a plasma miRNA-CEA biomarker panel for early detection of lung cancerCancer Treatment and Research Communications · 2026
  6. Real-world efficacy and sequential therapy patterns after avelumab maintenance in metastatic urothelial carcinoma: a Brazilian multicenter retrospective cohort studyCancer Treatment and Research Communications · 2026
  7. Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trialCancer Treatment and Research Communications · 2026
  8. Artificial intelligence-powered evaluation of the pathologic response to preoperative therapy in non-small cell lung cancerCancer Treatment and Research Communications · 2026
  9. FGF/FGFR signaling in hepatocellular carcinoma: From molecular mechanisms to biomarker-guided therapyCancer Treatment and Research Communications · 2026
  10. Renal function decline after radical nephroureterectomy: Longitudinal analysis and predictive factors in upper tract urothelial carcinomaCancer Treatment and Research Communications · 2026
  11. Global prevalence of sexual dysfunction in women with ovarian cancer: a systematic review and meta-analysisCancer Treatment and Research Communications · 2026
  12. The parasitic synapse: How gliomas hijack the connectome for malignant gainCancer Treatment and Research Communications · 2026
  13. Real-world treatment persistence of first-line atezolizumab in elderly patients with PD-L1–high NSCLC: comparison with pembrolizumabCancer Treatment and Research Communications · 2026
  14. Cell-block for diagnostic cytopathology: A touchstone in diagnosisCancer Treatment and Research Communications · 2026
  15. Induction immunochemotherapy followed by definitive radiotherapy for inoperable NSCLC: A retrospectivecohort studyCancer Treatment and Research Communications · 2026
  16. Prognosis following the initiation of various immune checkpoint inhibitor therapies in TTF-1-negative non-small cell lung cancerCancer Treatment and Research Communications · 2026
  17. An observational study to identify selection criteria for initiation of different first line treatment options in patients with non-small cell lung cancerCancer Treatment and Research Communications · 2026
  18. BRK/PTK6 in breast cancer: prognostic and therapeutic significanceCancer Treatment and Research Communications · 2026
  19. Patterns and outcomes of emergency department visits by patients receiving immune checkpoint inhibitors: a single-center, retrospective studyCancer Treatment and Research Communications · 2026
  20. In vitro functional evaluation of soluble single domain antibodies targeting the HER2 dimerization domainCancer Treatment and Research Communications · 2026
  21. Evaluation of preoperative plasma cytokines for the diagnosis and prognosis of malignant lung nodulesCancer Treatment and Research Communications · 2026
  22. Metabolic Reprogramming Of Macrophages In Breast Cancer: Mechanisms And Therapeutic ImplicationsCancer Treatment and Research Communications · 2026
  23. Metformin in cancer immunotherapy: knowledge mapping of an evolving field through bibliometric analysis (2007–2026)Cancer Treatment and Research Communications · 2026
  24. Frailty, initial attrition and feasibility of novel platinum-free options for advanced non-small-cell lung cancer in the real-world settingCancer Treatment and Research Communications · 2026
  25. Applying the health belief model to explore healthcare provider and patient perspectives on homologous recombination deficiency testing in cancer: A narrative reviewCancer Treatment and Research Communications · 2026
  26. A randomized controlled trial of home-based combined exercise training for improving inflammatory markers and physical function in breast cancer survivorsCancer Treatment and Research Communications · 2026
  27. An integrated single-cell and Mendelian randomization analysis of stromal features in Asherman’s syndrome and endometrial cancerCancer Treatment and Research Communications · 2026
  28. Multi-omics and molecular biomarkers in breast cancer: a comprehensive review of diagnostic, prognostic, and predictive applicationsCancer Treatment and Research Communications · 2026
  29. Acute respiratory viral inflammation and metastatic dormancy: direct evidence, mechanistic convergence, and research prioritiesCancer Treatment and Research Communications · 2026
  30. Radium-223 alters the levels of soluble immune regulators in the plasma of patients with metastatic castrate-resistant prostate cancerCancer Treatment and Research Communications · 2026
  31. Prognostic value of FUBP1 in Colorectal cancer and association with immune microenvironment characteristicsCancer Treatment and Research Communications · 2026
  32. Clinical features and multidimensional prognostic model of EGFR-TKI acquired resistance in NSCLC patients with or without brain metastasesCancer Treatment and Research Communications · 2026
  33. Identification of biomarkers associated with enhanced survival in lung cancer patients undergoing immune checkpoint inhibitor treatmentCancer Treatment and Research Communications · 2026
  34. Post-translational acylation of proteins in colorectal cancerCancer Treatment and Research Communications · 2026
  35. The CALLY recovery ratio: a novel dynamic immunonutritional biomarker for predicting survival after curative gastrectomy in gastric cancerCancer Treatment and Research Communications · 2026
  36. Clinical and epidemiological characteristics of colorectal cancer patients in a hospital-based series from Iran, 2009–2019Cancer Treatment and Research Communications · 2026
  37. Primary language and its association with patient-reported treatment adherence and satisfaction in genitourinary oncologyCancer Treatment and Research Communications · 2026
  38. Molecular characterization of salivary cancers: Patterns of genomic alterations and potential for impact on therapeutic choicesCancer Treatment and Research Communications · 2026
  39. Cancer-associated fibroblasts during and after therapy: disentangling state, function and persistenceCancer Treatment and Research Communications · 2026
  40. Integrative transcriptomic identification of potential common biomarkers between non-obstructive azoospermia and papillary thyroid cancer via multi-algorithmic machine learning and network biology approachesCancer Treatment and Research Communications · 2026
  41. Griseofulvin as a dual-action agent against glioblastoma: anti-tumor effect and enhancement of 5-ALA photodynamic diagnosis in stem-like cellsCancer Treatment and Research Communications · 2026
  42. Validating raloxifene-mediated restoration of DNMT–TET epigenetic balance in breast and lung cancerCancer Treatment and Research Communications · 2026
  43. Drug-related problems in pediatric, adult and geriatric cancer patients: A systematic reviewCancer Treatment and Research Communications · 2026
  44. Self-supervised multimodal swin UNETR for PET/CT segmentation of diffuse large B-cell lymphomaCancer Treatment and Research Communications · 2026
  45. Treatment patterns and clinical outcomes among patients with metastatic castration-resistant prostate cancer: a multinational retrospective medical record reviewCancer Treatment and Research Communications · 2026
  46. A direct comparison of butyrate, 4-phenylbutyrate, and β-hydroxybutyrate in an in vitro tumor therapy modelCancer Treatment and Research Communications · 2026
  47. Hereditary cancer syndromes as a model for precision oncology: the paradigms of HRD and MSICancer Treatment and Research Communications · 2026
  48. Mutational landscape of lung adenocarcinoma in CzechiaCancer Treatment and Research Communications · 2026
  49. Rediscovering Kaposi Sarcoma in North Africa: Thirteen years of HIV-negative cases and survival insights from MoroccoCancer Treatment and Research Communications · 2026
  50. Beyond Exons 19 and 21: mapping the clinical and molecular diversity of uncommon EGFR mutations in a Brazilian NSCLC cohortCancer Treatment and Research Communications · 2026